DS 1001

Drug Profile

DS 1001

Alternative Names: DS-1001; DS-1001b

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class Antineoplastics
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma

Most Recent Events

  • 01 Dec 2016 Investigation in Glioma in Japan (PO) before December 2016
  • 01 Dec 2016 Phase-I clinical trials in Glioma in Japan (PO) (NCT03030066 and JapicCTI163479)
  • 01 Dec 2016 Daiichi Sankyo plans a phase I trial for Glioma (Recurrent, Second-line therapy or greater) in Japan (PO) (JapicCTI163479)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top